Numerous studies have reported that EGFR mutations frequently occurred especially in substitution of arginine for leucine at amino acid position 858 (L858R) within exon 21, and an in-frame deletion within exon 19 (delE746-A750) in NSCLC patients, which accounts for 85% of EGFR mutations [24–26]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.